Loading stock data…
$6.19-0.20 (-3.13%)
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen, Inc. in the Healthcare sector is trading at $6.19 with a market capitalization of $2.5B. Wall Street consensus targets $13.65 (3 analysts), implying a +120.5% move over the next 12 months. The stock is currently 31% below its 52-week high of $8.98, remaining 18.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $54.98M↑ | $23.25M↑ | $4.57M↑ | $2.92M↑ | $856,000 |
| Gross Profit | $52.17M↑ | $20.69M↑ | $2.97M↑ | $1.89M↑ | -$236,000 |
| Operating Income | $22.64M↑ | -$5.99M↑ | -$21.67M↑ | -$34.48M↓ | -$27.86M |
| Net Income | $20.07M↑ | -$7.93M↑ | -$23.50M↑ | -$146.34M↓ | -$26.64M |
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers the...